Pharmacological advances in the treatment of Insomnia

Current Pharmaceutical Design

Volumn 17, Issue 15, 2011, Pages 1471-1475

  Richey, Sarah M ^a   Krystal, Andrew D ^b  

^a KAISER PERMANENTE MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Hypnotic; Insomnia; Pharmacology

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR; AGOMELATINE; ALMOREXANT; DOXEPIN; ESTAZOLAM; ESZOPICLONE; FLURAZEPAM; HYPNOTIC SEDATIVE AGENT; MELATONIN; MK 4035; NELOTANSERIN; OREXIN; OXYBATE SODIUM; PLACEBO; QUAZEPAM; RAMELTEON; SEDATIVE AGENT; TEMAZEPAM; TRIAZOLAM; UNCLASSIFIED DRUG; ZALEPLON; ZOLPIDEM; ZOLPIDEM TARTRATE;

ANXIETY; ANXIETY DISORDER; ARTICLE; CIRCADIAN RHYTHM; COMORBIDITY; DEPRESSION; DRUG HALF LIFE; HUMAN; INSOMNIA; LOW DRUG DOSE; MOOD DISORDER; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG TOLERANCE; HUMANS; HYPNOTICS AND SEDATIVES; SLEEP; SLEEP INITIATION AND MAINTENANCE DISORDERS;

EID: 80455165975     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211796197052     Document Type: Article

References (36)

1. Ohayon M. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev 2002; 6: 97-111.
2. Krystal AD. A compendium of placebo-controlled trials of the risks/benefits of pharmacologic treatments for insomnia: the empirical basis for U.S. clinical practice. Sleep Med Rev 2009; 13(4): 265-74.
3. McCall WV, Erman M, Krystal AD, Rosenberg R, Scharf M, Zammit GK. A polysomnography study of eszopiclone in elderly patients with insomnia. Curr Med Res Opin 2006; 22: 1633-42.
4. Roth T, Soubrane C, Titeux L, Walsh JK. Zoladult Study Group. Efficacy and safety of zolpidem-MR: A double-blind, placebocontrolled study in adults with primary insomnia. Sleep Med 2006; 7(5): 397-406.
5. Elie R, Rüther E, Farr I, Emilien G, Salinas E. Sleep latency is shortened with 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. Zaleplon Clinical Study Group. J Clin Psychiatry 1999; 60(8): 536-544.
6. Walsh JK, Krystal AD, Amato DA, et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep quality, quality of life and work limitations. Sleep 2007; 30: 959-968.
7. Nutt DJ, Stahl SM. Searching for perfect sleep: the continuing evolution of GABAA receptor modulators as hypnotics. J Psychopharmacol 2010; 24(11): 1601-12.
8. Principles and Practices of Sleep Medicine, 5th ed. Kryger M, Roth, T, Dement, W 2011, Elsevier Saunders, St. Louis pp 905-913, 920.
9. Hajak G, Müller WE, Wittchen HU, Pittrow D, Kirch W. Abuse and dependence potential for the nonbenzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data. Addiction 2003; 98(10): 1371-8.
10. Pharamcology, 4th Ed. RA Harvey, PC Champe. Lippincott Williams & Wilkins Philadelphia 2009 pp 112-115, 145-147.
11. Vermeeren A. Residual effects of hypnotics. CNS Drugs 2004; 18: 297-328.
12. Ohayon MM, Caulet M, Lemoine P. Comorbidity of mental and insomnia disorders in the general population. Compr Psychiatry 1998; 39: 185-197.
13. Taylor DJ, Lichsteain KL, Durrence HH, et al. Epidemiology of insomnia, depression and anxiety. Sleep 2005; 28: 1457-1464.
14. Fava M, McCall WV, Krystal A, et al. Eszopiclone coadministered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatry 2006; 59: 1052-60.
15. Pollack M, Kinrys G, Krystal A, et al. Eszopiclone co-adminstered with fluoxetine in patients with insomnia and generalized anxiety disorder. Arch Gen Psychistry 2008; 65: 551-562.
16. Fava M, Asnis GM, et al. Improved insomnia symptoms and sleeprelated next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended release 12.5mg and escitalopram treatment: a randomized controlled tiral. J Clin Psychiatry 2010; e1-e15.
17. Staner C, Joly F, Jacquot N, et al. Sublingual zolpidem in early onset of sleep compared to oral zolpidem: polysomnographic study in patients with primary insomnia. Curr Med Res Opin 2010; 26(6): 1423-31.
18. Roth T, Hull SG, Lankford DA, et al. Low-dose sublingual zolpidem tartrate is associated with dose-related improvement in sleep onset and duration in insomnia characterized by middle-of-thenight (MOTN) awakenings. Sleep 2008; 31: 1277-1284.
19. Erman M, Seiden D, Zammit G, Sainati S, Zhang J. An efficacy, safety, and dose-response study of ramelteon in patients with chronic primary insomnia. Sleep Med 2006; 7(1): 17-24.
20. Uchimura N, Ogawa A, Hamamura M, Hashimoto T, Nagata H, Uchiyama M. Efficacy and safety of ramelteon in Japanese adults with chronic insomnia: a randomized, double-blind, placebocontrolled study. Expert Rev Neurother 2011; 11(2): 215-224.
21. Quera-Salva M, Lemoine P, Guilleminault C. Impact of the novel antidepressant agomelatine on disturbed sleep-wake cycles in depressed patients. Hum. Psychopharmacol Clin Exp 2010; 25: 222-229.
22. Stahl SM, Fava M, Trivedi MH, et al. Agomelatine in the Treatment of Major Depressive Disorder: An 8-Week, Multicenter, Randomized, Placebo-Controlled Trial. J Clin Psychiatry 2010; 71: 616-626.
23. Roth T, Rogowski R, Hull S, et al. Efficacy and safety of doxepin 1mg, 3mg and 6mg in Adults with Primary Insomnia. Sleep 2007; 30: 1555-1561.
24. Scharf M, Rogowski R, Hull S, et al. Efficacy and safety of doxepin 1mg, 3mg and 6mg in elderly patients with primary insomnia: a randomized, double-blind, placebo-controlled crossover study. J Clin Psychiatry 2008; 69: 1557-64.
25. Krystal AD, Durrence HH, Scharf M, et al. Efficacy and safety of doxepin 1mg and 3mg in a 12-week sleep and outpatient trial of elderly subjects with chronic primary insomnia. Sleep 2010; 33(11): 1553-61.
26. Brisbare-Roch C, et al. Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat Med 2007; 13: 150-155.
27. Actelion presentations, World Sleep Congress, Cairns, Australia, Sept 3-6, 2007.
28. Actelion Pharmaceuticals. Allschwil, Switzerland: Actelion Pharmaceuticals Ltd; c2011 [updated 2011 Feb 17; cited 2011 Feb 26] Available from: http://www1.actelion.com/en/our-company/newsand-events/index.page?newsId=1483135
29. Merck. Whitehouse Station, NJ: Merck & Co, Inc; c2009-2010 [cited 2011 Feb 26] Available from: http://www.merck.com/newsroom/news-release-archive/research-anddevelopment/2010_0609.html
30. Abrams JK, Johnson PL, Hay-Schmidt A, et al. Serotonergic systems associated with arousal and vigilance behaviors following administration of anxiogenic drugs. Neuroscience 2005; 133: 983-997.
31. Morairty SR, et al. Selective 5HT2A and 5 HT6 receptor antagonists promote sleep in rats. Sleep 2008; 31(1): 34-44.
32. Rosenberg R, et al. ADP125, a selective serotonin 5HT2A receptor inverse agonist, significantly improves sleep maintenance in primary insomnia. Sleep 2008; 31(12): 1663-1671.
33. Arena Pharmaceuticals. San Diego, CA: Arena Pharmaceuticals, Inc; c2000-2011 [updated 2001 Feb 25; cited 2011 Feb 26] Available from: http://invest.arenapharm.com/releases.cfm?ReleasesType=&Year=2008
34. Mamelak M, Scharf MB, Woods M. Treatment of narcolepsy with γ-hydroxybutryate. A review of clinical and sleep laboratory findings. Sleep 1986; 9(1): 285-289.
35. Russel IJ, Perkins AT, Michalek JE. Sodium oxybate relieves pain and improves function in fibromyalgia syndrome: a randomized, double-blind, placebo-controoled, multicenter clinical trial. Arthritis Rheum 2009; 60(1): 299-309.
36. Kuo TF, Stowers P, Tortora L, et al. Sodium oxybate and zolpidem in the treatment of chronic insomnia: a randomized, double-blind, double dummy, placebo controlled 3-arm, parallel group study [abstract]. Sleep 2009; 32(A Suppl): A273.